All In Biotech

Drug Trial Radar · NCT05345418

Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency

Evaluation of the Safety and Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency: A Phase I/IIa Randomised Crossover Trial

Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

158

Planned (sponsor's estimate)

Start

Apr 1, 2022

Primary completion

Jun 1, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Vinmec Research Institute of Stem Cell and Gene TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 50 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sexual functional deficiency affects largely the physical conditions, life and sexual quality of the patients. Hypogonadism affects about 4 to 5 million men in the US, and the incidence increases with age. In our recent phase I clinical trial, we have shown that intravenous adipose - derived MSC administration was safe in female and male patients with hormone deficiency. Post-transplantation sexual satisfaction was observed in all patients enrolled in this study. Testosterone levels in males increased significantly after transplantation and were maintained at high levels for up to 6 months before decreasing again at the 12-month follow-up. The aim of this clinical trial was to assess the safety and effectiveness of allogeneic administration of MSCs in middle-aged people with sexual functional deficiency.

Conditions

  • Sexual Dysfunction Male

Interventions

  • Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual DeficiencyBiological

    Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of allogenic umbilical cord-derived mesenchymal stem cell administration for the treatment of hormone deficiency in maleTime frame: up to the 12-month period following treatment
  2. Testosterone levelsTime frame: up to the 12-month period following treatment
  3. Changes in sexual life quality using Aging Men Symptom (AMS)Time frame: up to the 12-month period following treatment
  4. Changes in sexual life quality through quantification of International Index of Erectile Function (IIEF)Time frame: up to the 12-month period following treatment
  5. Changes in sexual life quality through quantification of Sexual Quality of Life Questionnaire (SQoL-M)Time frame: up to the 12-month period following treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vinmec Research Institute of Stem Cell and Gene Technology

    Hanoi, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.